Alsactide (Synchrodyn) is synthesized heptadecapeptide analog of adrenocorticotropic hormone (ACTH) having a C-terminal amide group (butylamide) and the substitution of beta-alanine for serine in position 1 and of lysine for arginine in position 17. These modifications account for enhanced biological activity and uniquely demonstrated chronopharmacological properties. In adult healthy men, the tailoring of dosage and timing of peptide administration was successful in a selective and transient stimulation of glucocorticoid secretion, without a change in the plasma concentrations of aldosterone and testosterone. The clinical use of alsactide has provided new diagnostic information about subtle alterations of the adrenal function and has been valuable to presenting the rhythmic ordering of several functions, especially of those which are more dependent on the glucocorticoid modulation.

Fluoroethylcholine ion F-18 is ethylcholine labeled with fluorine F 18, a positron-emitting isotope. Fluorine F18 fluoroethylcholine incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, yielding a phosphoryl derivative, and finally is integrated into cellular phospholipids, probably primarily into a phosphatidyl derivative; concentration of this agent in tumor cells as various fluorine F 18 fluoroethylcholine derivatives enables tumor imaging using positron emission tomography (PET). Choline kinase, the enzyme responsible for the phosphorylation of choline, is frequently up-regulated in human tumor cell lines. F18-fluoroethylcholine is used for imaging of prostate cancer and brain tumors, mainly in Europe and Japan.

Iometopane (RTI-55, beta-CIT) is a cocaine congener, binding to the neuronal dopamine and serotonin reuptake transporters affinity of Kd = 0.3 nM. Radiopharmaceutical forms of RTI-55 are used in single-photon emission computer tomography. Radioisotops 123I and 125I are favored, but 124I also used as a positron emitter to diagnose Parkinson's Disease.

Erbium-169 citrate is anti-inflammatory and antirheumatic radiopharmaceutical agent. Erbium-169 decays with half-life 9.4 days by the emission of beta particle and very low energy gamma radiation. The average radiation penetration is 0.3 mm in the soft tissues and 0.2 mm in the cartilage. Colloid Er-169 is used in radiosynovectomy on rheumatoid arthritis patients whose condition is resistant to standard methods of treatment. During this procedure, colloid erbium-169 citrate is directly injected into the synovial cavity of the affected joint. The data indicate that after intra-articular injection, radioactive colloid particles are picked up by superficial synovial cells. Under the effect of irradiation, necrosis of the superficial synovial layer takes place, followed by phagocytosis of the necrotic tissue and delineated inflammatory flare. This temporarily halts synovitis and improves synovial joint function.

Technetium Tc 99m Gluconate is a radiopharmaceutical agent that has been used for the diagnosis of kidney disease. Although Technetium Tc 99m Gluconate is of a hydrophilic character, it shows high plasma protein binding (50–70%). Therefore, both glomerular filtration and tubular excretion by the kidneys occur with slow pharmacokinetics, and only 70% of the injected activity is washed out after one day. This is the reason why Technetium Tc 99m Gluconate is no longer used for renal studies. Owing to its low stability, Technetium Tc 99m Gluconate is used (i) for red blood cell labeling and (ii) as a ligand exchange partner for labeling other molecules